Predicting prognosis of rectal cancer patients with total mesorectal excision using molecular markers

Table 2 Distribution of stage II or III patients with or without adjuvant chemotherapy

		Adjuvant chemotherapy(n = 179)				P
		No		Yes
		Cases	%	Cases	%
N staging	N0	114	68.2	33	35.9	< 0.05
	N1	33	19.8	29	31.5
	N2	20	12	30	32.4
T staging	T1-2	90	53.9	11	12	< 0.05
	T3	38	22.7	47	51
	T4	39	23.4	34	37
Differentiation	High-Medium	145	86.8	77	83.7	> 0.05
	Low	22	13.2	15	16.3
Lymphovascular invasion	None	19	11.4	14	15.6	> 0.05
	Yes	148	88.6	78	84.4
Neural invasion	None	14	8.4	7	7.6	> 0.05
	Yes	154	91.6	85	92.4